| (Values in U.S. Thousands) | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -32,670 | -15,180 | -13,530 | -11,100 | -14,590 |
| Net Income Growth | -115.22% | -12.20% | -21.89% | +23.92% | -146.04% |
Azurrx Biopharma Inc (AZRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Azurrx Biopharma, Inc. is a biopharmaceutical company. It focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. The company's product pipeline consists of MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency and AZX1101, a recombinant enzyme for the prevention of hospital-acquired C.difficile infections. Azurrx Biopharma, Inc. is headquartered in New York City.